Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SB-728mR-T · 1 trial · 1 indication
Number of Participants with Treatment related Adverse Events in subjects who received any portion of the SB-728mR-T infusion
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | - |
| Cohort 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SB-728mR-T | GENETIC | -SB-728mR-T infusions of 2 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells) |
| Cyclophosphamide | DRUG | \- IV cyclophosphamide 1 g/m2 two days prior to the first SB-728mR-T infusion |
Inclusion Criteria: * Male or female, 18 years of age or older with documented HIV diagnosis. * Must be willing to comply with study-mandated evaluations; including discontinuation of current antiretroviral therapy during the treatment interruption. * Initiated HAART therapy within (≤) 1 year of HI...
SB-728mR-T is an investigational gene therapy being studied for the treatment of Human Immunodeficiency Virus (HIV) infection. It is designed for HIV-infected subjects who are on highly active antiretroviral therapy (HAART). The therapy is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
SB-728mR-T is a gene therapy that involves modifying a patient's own T cells. While the specific molecular target is not disclosed, the therapy is designed to be used in HIV-infected individuals on HAART. It is being investigated for its potential to control HIV infection through genetic modification of immune cells.
SB-728mR-T is being developed by Sangamo Therapeutics, Inc., a biopharmaceutical company. Sangamo is publicly traded on the NASDAQ under the ticker symbol SGMO. The company is conducting clinical research on this investigational gene therapy for HIV.
SB-728mR-T is in Phase 1 clinical development. It is an investigational gene therapy and has not been approved by the FDA or any other regulatory agency. The therapy is still in early-stage clinical trials to evaluate its safety and potential efficacy in HIV-infected patients.
SB-728mR-T has been studied in one completed clinical trial, NCT02225665, titled "Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART." This Phase 1 trial enrolled 8 participants in the United States and was a controlled study, though it was not randomized or double-blinded.
SB-728mR-T is a unique investigational gene therapy developed by Sangamo Therapeutics. No alternative names for this drug have been reported. It is distinct from other HIV treatments and is being studied specifically as a cell-based gene therapy approach for HIV infection.